Are GLP-1s Worth What They Cost? 10 Economic Analyses (2026)

10 papers · each one re-checked on PubMed · last verified October 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

More coverage decisions have turned on economics than on any clinical question. The convention in US health economics is that a treatment costing under about $100,000 per quality-adjusted life year is worth buying. At list price, for obesity alone, these drugs come in well above that in nearly every independent model. Three things change the verdict, and it helps to know which one an argument is leaning on: restricting to patients who already have cardiovascular disease, using the rebated net price instead of the sticker price, or treating the drug as time-limited rather than permanent. Check who paid for a model before weighing its number. Three of the models below are sponsor-funded, each says so, and all three come out more favorable than the independent ones.

Ranked papers

#1

Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults

Hwang JH, Laiteerapong N, Huang ES, Kim DD · JAMA Health Forum · 2025

What it measured: Cost per year of healthy life gained, over a lifetime, from a US health-system view

The independent benchmark, and the harshest number in this literature: a lifetime simulation, at current net prices, putting tirzepatide at roughly $197,000 per quality-adjusted life year and semaglutide at roughly $468,000, against lifestyle change alone, in US adults who would qualify for the drugs (85% of them with at least one weight-related condition). The authors translate it into the term that matters most for policy. Prices would have to fall a further 30.5% for tirzepatide and 81.9% for semaglutide to reach $100,000 per quality-adjusted life year. Every counterargument on this page is in some sense a response to this paper.

PMID 40085108 ↗DOI 10.1001/jamahealthforum.2024.5586 ↗

#2

Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity

Hwang JH, Laiteerapong N, Huang ES, Mozaffarian D · JAMA Health Forum · 2025

What it measured: What Medicare drug coverage would cost over ten years, minus medical savings

The companion analysis, asking what Medicare coverage for obesity would cost rather than whether it is worth it. In the base case, ten-year Medicare drug costs came to $65.9 billion, offset by only $18.2 billion in prevented disease, for a net $47.7 billion. Even a cautious scenario with low uptake and a deeper discount still cost a net $8 billion. It was written in response to the Biden administration's proposal to expand Part D coverage, which CMS floated in November 2024 and which was never finalized.

PMID 40279111 ↗DOI 10.1001/jamahealthforum.2025.0905 ↗

#3

Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes

McEwan P, Bøg M, Faurby M, Foos V · J Med Econ · 2025

What it measured: Cost per year of healthy life gained, in patients who already have heart disease

A model of the SELECT population that calls Wegovy cost-effective at US list price, at $136,271 per quality-adjusted life year (or $32,219 with an estimated 48% rebate), in patients with overweight or obesity plus existing heart disease and no diabetes. It clears the bar only because the authors used a $150,000 threshold. Over a lifetime horizon, most of the modeled savings came from type 2 diabetes avoided ($14,431 a person) rather than from cardiac events ($1,512). Novo Nordisk funded it. That alone does not make it wrong, though the assumptions behind a favorable result deserve reading, not just the headline.

PMID 39882599 ↗DOI 10.1080/13696998.2025.2459529 ↗

#4

Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States

Kim N, Wang J, Burudpakdee C, Song Y · J Manag Care Spec Pharm · 2022

What it measured: Cost per year of healthy life gained against diet and exercise, over 30 years

The original US analysis, from before the cardiovascular data existed: over 30 years, semaglutide came out between $23,556 and $144,296 per quality-adjusted life year depending on the comparator (no treatment, diet and exercise, or another weight drug), which the authors call cost-effective against every one at a $150,000 threshold. Novo Nordisk funded it, and company employees were among the authors. It was overtaken as soon as the cardiovascular data arrived.

PMID 35737858 ↗DOI 10.18553/jmcp.2022.28.7.740 ↗

#5

Modeling potential cost-effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity

Hoog MM, Kan H, Deger KA, Sorensen S · Obesity (Silver Spring) · 2025

What it measured: Cost per year of healthy life gained against lifestyle change, over a lifetime

The tirzepatide counterpart at $125,053 to $146,331 per quality-adjusted life year against lifestyle change, depending on dose, which the authors call cost-effective at a $150,000 threshold. That is well below the independent estimate of about $197,000 for the same drug. Read the two together, because the gap between them is instructive. It comes down to assumptions about how much weight comes back after stopping, how much downstream disease gets prevented, and whether the model uses list or net price. Eli Lilly funded this one. It is the sponsor-side bookend.

PMID 40512029 ↗DOI 10.1002/oby.24310 ↗

#6

Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity

Mital S, Nguyen HV · JAMA Netw Open · 2023

What it measured: Cost per year of healthy life gained in adolescents, over 10 years

The adolescent analysis, and the one place where the arithmetic behaves unexpectedly. Modeling teenagers aged 12 to 17 with severe obesity over 10 years, semaglutide came out near $1.08 million per quality-adjusted life year, liraglutide cost more and did less than semaglutide, and the much older phentermine-topiramate combination was the only cost-effective drug, at $93,620. Ten years is a short horizon for a teenager, and the authors say more research is needed on long-term efficacy and on how long adolescents stay on treatment.

PMID 37824146 ↗DOI 10.1001/jamanetworkopen.2023.36400 ↗

#7

Net prices of new antiobesity medications

Hernandez I, Sullivan SD · Obesity (Silver Spring) · 2024

What it measured: What payers actually pay after rebates, against the list price

The paper that undermines the inputs of nearly every other analysis here. Using manufacturer revenue data, it estimates discounts of 41% off list for the GLP-1 drugs approved for obesity (net prices of $717 to $761 a month) and 54 to 59% for the diabetes versions. If that is right, most published cost-effectiveness ratios overstate the real burden on payers by a wide margin. That is precisely the argument manufacturers make, here resting on independent work. It is the strongest reason to distrust any analysis anchored on sticker price.

PMID 38228492 ↗DOI 10.1002/oby.23973 ↗

#8

Balancing innovation and affordability in anti-obesity medications: the role of an alternative weight-maintenance program

Kim DD, Hwang JH, Fendrick AM · Health Aff Sch · 2024

What it measured: Budget impact and cost-effectiveness of induction-plus-maintenance dosing

The most practically interesting model on this page asks what happens if the drug is used as induction rather than forever: full dose to reach target weight, then a step down to a cheaper maintenance approach. Across a wide range of assumed prices and effectiveness, the maintenance approach gave up a little health and saved a lot of money over a lifetime. Whenever it cost less than 70% of the full-dose drug, it saved money overall, however well it held the weight. The catch is unavoidable, and this site documents it elsewhere. The withdrawal trials show weight comes back. The model's value depends entirely on whether a cheaper maintenance strategy can hold it, which no trial has demonstrated.

PMID 38828004 ↗DOI 10.1093/haschl/qxae055 ↗

#9

A cost-effectiveness analysis of behavioural, pharmacological, and surgical obesity treatments in Canada

Gupta N, Babyak A, Chorbajian A, Tardio V · Diabetes Obes Metab · 2025

What it measured: Cost per year of healthy life gained under Canadian pricing, drugs against surgery

The check on whether this is only a US problem. In Canadian adults with class III obesity (BMI 40 or more), modeled over 40 years from the public payer's view, neither semaglutide nor tirzepatide was cost-effective at current prices against a CAD $50,000 threshold. Semaglutide cost more and did less than other options, and gastric bypass beat tirzepatide, delivering the most health at CAD $44,667 per quality-adjusted life year. The authors add that lower drug prices could change the verdict, so the problem is price, in Canada too.

PMID 40686094 ↗DOI 10.1111/dom.16627 ↗

#10

GLP-1 receptor agonists for treating obesity without diabetes: A systematic review and meta-analysis of economic evaluations

Dhippayom T, Meraz M, Lee H, Hur C · Diabetes Obes Metab · 2026

What it measured: Cost-effectiveness pooled across nine published economic analyses

The synthesis, and the entry to read if you only read one. It pooled nine published economic evaluations (23 comparisons) from high-income countries and found semaglutide and liraglutide generally not cost-effective for obesity without diabetes, whether against no treatment or against lifestyle programs. The authors add two caveats: the drugs may be cost-effective in some subgroups over longer horizons, and most models counted only weight-related outcomes, which may understate their value.

PMID 41365841 ↗DOI 10.1111/dom.70322 ↗

About this list

Obesity medicine throws up the same handful of questions over and over, and we answer them with ranked lists anchored to the papers themselves. On 2026-10-30 every citation below was put back through PubMed. Where a trial has a registry entry, the card carries that link too, alongside the PubMed one.

Browse our full index of research lists or our long-form research articles.